Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.91 +5.5%	$2.10	$1.63 ▼ $4.66	$10.50M	0.81	645,332 shs	65,342 shs
ENLV Enlivex Therapeutics	$1.05 +1.9%	$1.26	$0.81 ▼ $2.10	$24.36M	0.8	1.30 million shs	887,884 shs
SLGL Sol-Gel Technologies	$22.67 -12.1%	$10.98	$4.01 ▼ $26.89	$71.87M	1.21	24,984 shs	91,055 shs
TELO Telomir Pharmaceuticals	$1.45 -3.3%	$1.62	$1.12 ▼ $8.40	$48.42M	-0.67	441,320 shs	169,180 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	+5.52%	-0.52%	-20.42%	-3.05%	-34.14%
ENLV Enlivex Therapeutics	+1.94%	-42.31%	-10.26%	+7.69%	-14.63%
SLGL Sol-Gel Technologies	-12.13%	+46.83%	+128.07%	+198.68%	+277.83%
TELO Telomir Pharmaceuticals	-3.33%	-2.68%	-29.61%	-30.95%	-73.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCDA BioCardia	3.2309 of 5 stars	3.8	5.0	0.6	2.5	0.6
ENLV Enlivex Therapeutics	3.3301 of 5 stars	3.7	5.0	2.9	0.8	0.6
SLGL Sol-Gel Technologies	1.0144 of 5 stars	0.0	3.0	3.8	1.7	0.0
TELO Telomir Pharmaceuticals	2.6734 of 5 stars	3.8	2.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCDA BioCardia	3.50	Strong Buy	$25.00	1,208.90% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	852.38% Upside
SLGL Sol-Gel Technologies	0.00	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	934.48% Upside

Current Analyst Ratings Breakdown

Latest BCDA, TELO, ENLV, and SLGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCDA BioCardia	N/A	N/A	N/A	N/A	($0.33) per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
SLGL Sol-Gel Technologies	$11.54M	5.48	N/A	N/A	$11.44 per share	1.98
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCDA BioCardia	-$7.95M	-$1.85	N/A	N/A	N/A	N/A	-19,117.42%	-246.92%	11/11/2025 (Estimated)
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
SLGL Sol-Gel Technologies	-$10.58M	-$1.23	N/A	N/A	N/A	-14.25%	-11.80%	-9.39%	N/A
TELO Telomir Pharmaceuticals	-$16.53M	-$0.54	N/A	N/A	N/A	N/A	-4,595.08%	-1,750.91%	11/11/2025 (Estimated)

Latest BCDA, TELO, ENLV, and SLGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/15/2025	Q2 2025	SLGL Sol-Gel Technologies	-$0.67	$4.17	+$4.84	$4.17	$2.86 million	$17.26 million
8/14/2025	Q2 2025	TELO Telomir Pharmaceuticals	-$0.08	-$0.17	-$0.09	-$0.17	N/A	N/A
8/11/2025	Q2 2025	BCDA BioCardia	-$0.50	-$0.40	+$0.10	-$0.40	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCDA BioCardia	N/A	0.33	0.33
ENLV Enlivex Therapeutics	N/A	7.20	7.20
SLGL Sol-Gel Technologies	N/A	7.32	5.12
TELO Telomir Pharmaceuticals	N/A	2.39	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCDA BioCardia	20.57%
ENLV Enlivex Therapeutics	1.02%
SLGL Sol-Gel Technologies	26.18%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
BCDA BioCardia	20.00%
ENLV Enlivex Therapeutics	12.28%
SLGL Sol-Gel Technologies	66.51%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCDA BioCardia	40	5.80 million	4.64 million	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable
TELO Telomir Pharmaceuticals	1	32.28 million	N/A	N/A

BCDA, TELO, ENLV, and SLGL Headlines

Recent News About These Companies

TELO Makes Progress Toward Human Trials

August 15, 2025 | msn.com

Telomir-1 inhibits key histone demethylase enzymes in vitro

August 12, 2025 | bioworld.comB

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...

August 8, 2025 | kansascity.comK

Telomir Flat on Trial Data Release

August 7, 2025 | baystreet.ca

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

August 7, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (TELO) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Telomir Pharmaceuticals Announces Promising Preclinical Results

July 26, 2025 | theglobeandmail.com

Telomir Pharmaceuticals stock surges on promising Progeria treatment results

July 25, 2025 | investing.com

TELO Announces Another Important Breakthrough

July 25, 2025 | finance.yahoo.com

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

July 24, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 5% - Here's What Happened

July 23, 2025 | marketbeat.com

Telomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer Results

July 18, 2025 | msn.com

Telomir Pharmaceuticals stock soars after promising cancer treatment data

July 18, 2025 | investing.com

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

July 18, 2025 | msn.com

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

July 18, 2025 | accessnewswire.comA

Telomir says data show Telomir-1 reversed epigenetic silencing

July 17, 2025 | msn.com

Telomir Pharmaceuticals Reveals Promising Preclinical Cancer Results

July 17, 2025 | tipranks.com

Telomir Pharmaceuticals Inc News (TELO) - Investing.com

July 1, 2025 | investing.com

Telomir Pharmaceuticals Reports Positive Preclinical Data

June 18, 2025 | tipranks.com

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

June 18, 2025 | accessnewswire.comA

Telomir Pharma’s Telomir-1 shows dose-dependent restoration of neurological, liver & kidney functions in preclinical for Wilson’s disease

June 14, 2025 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA, TELO, ENLV, and SLGL Company Descriptions

BioCardia NASDAQ:BCDA

$1.91 +0.10 (+5.52%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.87 -0.04 (-2.30%)

As of 08/22/2025 07:59 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Enlivex Therapeutics NASDAQ:ENLV

$1.05 +0.02 (+1.94%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.03 -0.02 (-1.43%)

As of 08/22/2025 07:57 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies NASDAQ:SLGL

$22.67 -3.13 (-12.13%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$22.20 -0.47 (-2.07%)

As of 08/22/2025 07:39 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Telomir Pharmaceuticals NASDAQ:TELO

$1.45 -0.05 (-3.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.69%)

As of 08/22/2025 07:58 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time